BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Search i

Search help

  • Enter one or more search terms in the search field. Upper and lower case are not relevant.
  • As soon as you have entered three letters in the search field, various search words will be suggested from which you can choose one.
  • If you are searching for a certain group of words, put these words in double quotes. The hits will then contain the words in the order you entered, e.g. "medicines for children".
  • Multiple search terms can also be combined with the Boolean operators AND and OR. When using the operator AND, the results contain the intersection of all search terms. When using the operator OR, the hits contain one of the search terms or only individual search terms. The result set is therefore significantly larger. Please note that these operators must be written in capital letters.
  • If you receive a (too) large number of hits as a result of your search, you can narrow it down by using filters. These filter options appear to the left of the search results and are subdivided into:

    • category (e.g. safety of medicinal products, medical devices, code systems)
    • format (e.g. download, risk information, DHPCs)
    • time interval (e.g. last 30 days, older than ...)
  • Selected filters can be removed individually or all at once ("Show all results").
  • By default, search results are sorted by relevance, but they can also be sorted chronologically ("Latest entries first" or "Oldest entries first").

Enter search term

443 results

Results per page: 10 20 30

Zyvoxid® 2 mg/ml solution for injection (linezolid): Temporary shortage
PDF, 148KB, File is accessible
Date: 15. August 2013 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: linezolid

The company Pfizer Pharma GmbH is circulating information that the medicinal product Zyvoxid® 2 mg/ml solution for injection can currently not be supplied. This shortage is the result of manufacturing problems of one of the external …

Mucosolvan® Solution for injection (ambroxol hydrochloride)
PDF, 87KB, File is accessible
Date: 09. August 2013 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: ambroxol hydrochloride

Information on mixing with commercially available 5% glucose solution for infusion.

LInformation Letter on Roferon®-A (interferon alfa-2a)
PDF, 2MB, File is accessible
Date: 07. August 2013 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: interferon alfa-2a

The marketing authorisation holder Roche Pharma is circulating an information letter on a temporary shortage in the supply of Roferon®-A due to relocation of the production site.

Information Letter on PegIntron® (peginterferon alfa-2b)
PDF, 64KB, File is accessible
Date: 02. August 2013 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: peginterferon alfa-2b

Information on the correct use of the new pre-filled injection pen.

Dear Doctor Letter (Rote-Hand-Brief) on Erivedge® (vismodegib) PDF, 3MB, File is accessible Date: 31. July 2013 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: vismodegib

Important information for safe use, including information on contraceptive programmes.

Information Letter on VOTRIENT® (pazopanib)
PDF, 169KB, File is accessible
Date: 30. July 2013 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: pazopanib

Important change to frequency of serum liver test monitoring for hepatotoxicity.

DepoCyte® 50 mg injectable suspension (liposomal cytarabine for intrathecal injection): Back on the market as of 1 August 2013
PDF, 175KB, File is accessible
Date: 25. July 2013 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: liposomal cytarabine

As of 1 August 2013, DepoCyte® will be available again regularly on the German market.

Dear Doctor Letter (Rote-Hand-Brief) on Pedea® (ibuprofen as solution for injection): Shortage PDF, 401KB, File is accessible Date: 22. July 2013 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: ibuprofen

A temporary shortage in the supply of the medicinal product Pedea® for treatment of a haemodynamically significant patent ductus arteriosus Botalli in preterm newborn infants less than 34 weeks of gestational age has arisen due to the …

PlasmaVolume Redibag® by the company Baxter: Voluntary recall of the medicinal product PDF, 116KB, File is accessible Date: 18. July 2013 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: hydroxyethyl starch

The marketing authorisation holder Baxter is circulating information that its medicinal product PlasmaVolume Redibag® (active substance: hydroxyethyl starch (HES)) is being recalled voluntarily from the market and requests to stop using this …

Information Letter on Zofran® (ondansetron) and generic medicinal products: Risk of QTc prolongation PDF, 548KB, File is accessible Date: 18. July 2013 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: ondansetron

This communication contains updated information regarding intravenous use of ondansetron for prevention and treatment of chemotherapy-induced nausea, retching and vomiting (CINV), as well as new recommendations for repeated administration and …